Dosing of all patients in the trial has been successfully completed; final results are expected to be available in late Q2 2024.
Patent claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract.
All pharmacokinetic endpoints were achieved; all NaviCap„ devices performed as intended; no safety signals observed
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously...
Biora has entered into definitive agreements for the purchase and sale of 5,454,548 shares of common stock.
Biora Provides Corporate Update and Reports Q4 and FY23 Financial Results
Biora's management will host a webcast and conference call on Tuesday, March 26, 2024, after the close of financial markets.
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
Data from SAD cohort expected to be shared during March corporate update; MAD cohorts to begin dosing in March.